BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19417029)

  • 1. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
    Abraham J; Edgerly M; Wilson R; Chen C; Rutt A; Bakke S; Robey R; Dwyer A; Goldspiel B; Balis F; Van Tellingen O; Bates SE; Fojo T
    Clin Cancer Res; 2009 May; 15(10):3574-82. PubMed ID: 19417029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.
    Fox E; Widemann BC; Pastakia D; Chen CC; Yang SX; Cole D; Balis FM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1273-83. PubMed ID: 26486517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
    Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
    Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
    Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
    Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
    Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
    Oncologist; 2012; 17(4):512. PubMed ID: 22416063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.
    Yang SH; Lin CC; Lin ZZ; Tseng YL; Hong RL
    Invest New Drugs; 2012 Feb; 30(1):282-9. PubMed ID: 20809205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
    J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
    Pusztai L; Wagner P; Ibrahim N; Rivera E; Theriault R; Booser D; Symmans FW; Wong F; Blumenschein G; Fleming DR; Rouzier R; Boniface G; Hortobagyi GN
    Cancer; 2005 Aug; 104(4):682-91. PubMed ID: 15986399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
    Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
    J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
    Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients.
    Schilling T; Fiebig HH; Kerpel-Fronius S; Winterhalter B; Variol P; Tresca P; Heinrich B; Hanauske AR
    Invest New Drugs; 1996; 14(4):371-8. PubMed ID: 9157072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.